It will be interesting to see what more of these freedom of information requests about the SFO’s bogus sham investigation in GSK reveal..
The Serious Fraud Office spent £7.5 million on its corruption investigation into Glaxosmithkline before dropping the high-profile case.
It abandoned the five-year inquiry into alleged bribery at the FTSE 100 pharmaceuticals group in February after Lisa Osofsky, its new boss, reviewed the agency’s caseload.
The criminal investigation had been among the SFO’s longest-running and involved one of Britain’s biggest companies. Glaxo is valued at £76 billion and was formed through the merger in 2000 of Glaxo Wellcome and Smithkline Beecham.
The costs of the inquiry have been disclosed after a freedom of information request.